Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with metastatic breast cancer

Update Il y a 4 ans
Reference: ISRCTN23201971

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Not provided at time of registration and not expected to be available in the future


Inclusion criteria

  • FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer

Links